Introduction

bone defects, tooth
HYDROXYAPATITE
Post-extraction bone remodeling is an inevitable natural phenomenon and can lead to significant ridge dimensional changes with loss of height and width of the alveolar bone [DEXGEL is an in situ gelling hydrogel (WO/2011/070529A2) [The polysaccharide nature of DEXGEL mimics the extracellular matrix of native bone, offering excellent biocompatibility. We have previously reported DEXGEL suitability as a carrier of nanogels, cells, biomolecules, and granular ceramics [Bone graft synthetic substitutes are desired to overcome the limited source and significant morbidity associated with the harvesting of autologous bone grafts [This clinical study aimed to improve the performance and mode of administration of the glass-reinforced hydroxyapatite (HA) synthetic bone substitute, BL®, by association with dextrin-based hydrogel, DEXGEL, in the management of alveolar bone. Biocompatibility and bone ingrowth are crucial parameters to be examined for clinical acceptability. Herein, we report a study that aims to validate the clinical safety and efficacy of DEXGEL Bone (DEXGEL + BL®) for the treatment of bone defects through the following analysis: (a) assess the capacity and performance of DEXGEL both as a bioceramic vehicle and an adjuvant matrix in the bone regeneration process, (b) assess the volume and quality of regenerated bone, (c) assess the primary stability of the dental implant, and (d) assess granule stabilization and ease of clinical use. DEXGEL Bone will be applied as an intermediate alveolar regeneration procedure from tooth extraction moment to implant placement, aiming at achieving a volume of bone formed after 6 months equal to the initial post-extraction alveolar volume — primary endpoint.